Clinical Trial Update: Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 adjuvant trial evaluating Rezvilutamide with androgen deprivation therapy in AR-positive, high-risk salivary duct carcinoma. The study is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Duct Carcinoma

Drugs mentioned

• Rezvilutamide (rezvilutamide)

Snippet

Sponsor: Peking University First Hospital | Conditions: Salivary Gland Neoplasm Duct | Phase 2 | Status: RECRUITING